Clear Street’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Clear Street’s Portfolio KTTAW Stock Details KTTAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3	Buy	+380	New	+$3	﹤0.01%	1380
2025 Q3	–	Sell	-71	Closed	-$2	–	875
2025 Q2	$2	Hold	71	–	–	﹤0.01%	675
2025 Q1	$1	Hold	71	–	–	﹤0.01%	577
2024 Q4	$2	Sell	71 -29	-29%	-$1	﹤0.01%	586
2024 Q3	$3	Buy	+100	New	+$2	﹤0.01%	711
2023 Q4	–	Sell	-100	Closed	-$1	–	894
2023 Q3	$1	Sell	100 -100	-50%	-$2	﹤0.01%	1114
2023 Q2	$3	Buy	+200	New	+$6	﹤0.01%	1307

Other funds holding KTTAW

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Clear Street's KTTAW Position: Q2 2026 in Review

Clear Street opened a new position in Pasithea Therapeutics Warrants (KTTAW) in Q2 2026: 380 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #1380 among its holdings. This is a return to the name: Clear Street previously reported a position in KTTAW as recently as Q2 2025.

Clear Street first reported a position in KTTAW in Q2 2023 and has held it in 7 quarters since. 6 funds tracked by Wall St. Rank hold KTTAW as of Q2 2026.

Clear Street held 380 shares of Pasithea Therapeutics Warrants worth $3 as of Q2 2026.
Pasithea Therapeutics Warrants was a new Clear Street position in Q2 2026.
Pasithea Therapeutics Warrants made up ﹤0.01% of Clear Street's portfolio in Q2 2026, its #1380 holding.
Clear Street first reported a position in Pasithea Therapeutics Warrants in Q2 2023 and has held it in 7 quarters since.
6 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.